|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 20023 |
FusionGeneSummary for LPP_ADIPOQ |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: LPP_ADIPOQ | Fusion gene ID: 20023 | Hgene | Tgene | Gene symbol | LPP | ADIPOQ | Gene ID | 4026 | 9370 |
| Gene name | LIM domain containing preferred translocation partner in lipoma | adiponectin, C1Q and collagen domain containing | |
| Synonyms | - | ACDC|ACRP30|ADIPQTL1|ADPN|APM-1|APM1|GBP28 | |
| Cytomap | 3q27.3-q28 | 3q27.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | lipoma-preferred partnerLIM proteinlipoma preferred partner | adiponectin30 kDa adipocyte complement-related proteinadipocyte complement-related 30 kDa proteinadipose most abundant gene transcript 1 proteinadipose specific collagen-like factorgelatin-binding protein 28 | |
| Modification date | 20180519 | 20180527 | |
| UniProtAcc | Q93052 | Q15848 | |
| Ensembl transtripts involved in fusion gene | ENST00000448637, ENST00000312675, ENST00000543006, ENST00000471917, | ENST00000412955, ENST00000320741, ENST00000444204, | |
| Fusion gene scores | * DoF score | 29 X 22 X 11=7018 | 1 X 1 X 1=1 |
| # samples | 37 | 1 | |
| ** MAII score | log2(37/7018*10)=-4.24546277188585 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(1/1*10)=3.32192809488736 | |
| Context | PubMed: LPP [Title/Abstract] AND ADIPOQ [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | ADIPOQ | GO:0001934 | positive regulation of protein phosphorylation | 18431508 |
| Tgene | ADIPOQ | GO:0010642 | negative regulation of platelet-derived growth factor receptor signaling pathway | 12070119 |
| Tgene | ADIPOQ | GO:0010739 | positive regulation of protein kinase A signaling | 10982546 |
| Tgene | ADIPOQ | GO:0010745 | negative regulation of macrophage derived foam cell differentiation | 11222466 |
| Tgene | ADIPOQ | GO:0010804 | negative regulation of tumor necrosis factor-mediated signaling pathway | 10604883 |
| Tgene | ADIPOQ | GO:0010875 | positive regulation of cholesterol efflux | 18703020 |
| Tgene | ADIPOQ | GO:0010906 | regulation of glucose metabolic process | 17327472 |
| Tgene | ADIPOQ | GO:0030853 | negative regulation of granulocyte differentiation | 10961870 |
| Tgene | ADIPOQ | GO:0031953 | negative regulation of protein autophosphorylation | 12070119 |
| Tgene | ADIPOQ | GO:0032270 | positive regulation of cellular protein metabolic process | 18703020 |
| Tgene | ADIPOQ | GO:0032720 | negative regulation of tumor necrosis factor production | 10961870 |
| Tgene | ADIPOQ | GO:0032757 | positive regulation of interleukin-8 production | 19524870 |
| Tgene | ADIPOQ | GO:0033034 | positive regulation of myeloid cell apoptotic process | 10961870 |
| Tgene | ADIPOQ | GO:0034115 | negative regulation of heterotypic cell-cell adhesion | 10604883 |
| Tgene | ADIPOQ | GO:0034383 | low-density lipoprotein particle clearance | 11222466 |
| Tgene | ADIPOQ | GO:0034612 | response to tumor necrosis factor | 10604883 |
| Tgene | ADIPOQ | GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB signaling | 10982546 |
| Tgene | ADIPOQ | GO:0045599 | negative regulation of fat cell differentiation | 12021245 |
| Tgene | ADIPOQ | GO:0045650 | negative regulation of macrophage differentiation | 10961870 |
| Tgene | ADIPOQ | GO:0045715 | negative regulation of low-density lipoprotein particle receptor biosynthetic process | 11222466 |
| Tgene | ADIPOQ | GO:0045776 | negative regulation of blood pressure | 17327472 |
| Tgene | ADIPOQ | GO:0045892 | negative regulation of transcription, DNA-templated | 18431508 |
| Tgene | ADIPOQ | GO:0050765 | negative regulation of phagocytosis | 10961870 |
| Tgene | ADIPOQ | GO:0050805 | negative regulation of synaptic transmission | 17327472 |
| Tgene | ADIPOQ | GO:0070373 | negative regulation of ERK1 and ERK2 cascade | 12070119 |
| Tgene | ADIPOQ | GO:0071639 | positive regulation of monocyte chemotactic protein-1 production | 19524870 |
| Tgene | ADIPOQ | GO:0072659 | protein localization to plasma membrane | 18431508 |
| Tgene | ADIPOQ | GO:0090317 | negative regulation of intracellular protein transport | 18431508 |
| Tgene | ADIPOQ | GO:1900121 | negative regulation of receptor binding | 12070119 |
| Tgene | ADIPOQ | GO:1904706 | negative regulation of vascular smooth muscle cell proliferation | 12070119 |
| Tgene | ADIPOQ | GO:1904753 | negative regulation of vascular associated smooth muscle cell migration | 12070119 |
| Tgene | ADIPOQ | GO:2000279 | negative regulation of DNA biosynthetic process | 12070119 |
| Tgene | ADIPOQ | GO:2000481 | positive regulation of cAMP-dependent protein kinase activity | 18431508|19524870 |
| Tgene | ADIPOQ | GO:2000534 | positive regulation of renal albumin absorption | 18431508 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | BRCA | TCGA-D8-A1XW-01A | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-5UTR | ENST00000448637 | ENST00000412955 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| intron-5UTR | ENST00000448637 | ENST00000320741 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| intron-5UTR | ENST00000448637 | ENST00000444204 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| 5UTR-5UTR | ENST00000312675 | ENST00000412955 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| 5UTR-5UTR | ENST00000312675 | ENST00000320741 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| 5UTR-5UTR | ENST00000312675 | ENST00000444204 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| 5UTR-5UTR | ENST00000543006 | ENST00000412955 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| 5UTR-5UTR | ENST00000543006 | ENST00000320741 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| 5UTR-5UTR | ENST00000543006 | ENST00000444204 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| intron-5UTR | ENST00000471917 | ENST00000412955 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| intron-5UTR | ENST00000471917 | ENST00000320741 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
| intron-5UTR | ENST00000471917 | ENST00000444204 | LPP | chr3 | 187943315 | + | ADIPOQ | chr3 | 186570840 | + |
Top |
FusionProtFeatures for LPP_ADIPOQ |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| LPP | ADIPOQ |
| May play a structural role at sites of cell adhesion inmaintaining cell shape and motility. In addition to thesestructural functions, it may also be implicated in signalingevents and activation of gene transcription. May be involved insignal transduction from cell adhesion sites to the nucleusallowing successful integration of signals arising from solublefactors and cell-cell adhesion sites. Also suggested to serve as ascaffold protein upon which distinct protein complexes areassembled in the cytoplasm and in the nucleus.{ECO:0000269|PubMed:10637295, ECO:0000269|Ref.2}. | Important adipokine involved in the control of fatmetabolism and insulin sensitivity, with direct anti-diabetic,anti-atherogenic and anti-inflammatory activities. Stimulates AMPKphosphorylation and activation in the liver and the skeletalmuscle, enhancing glucose utilization and fatty-acid combustion.Antagonizes TNF-alpha by negatively regulating its expression invarious tissues such as liver and macrophages, and also bycounteracting its effects. Inhibits endothelial NF-kappa-Bsignaling through a cAMP-dependent pathway. May play a role incell growth, angiogenesis and tissue remodeling by binding andsequestering various growth factors with distinct bindingaffinities, depending on the type of complex, LMW, MMW or HMW.{ECO:0000269|PubMed:11479627}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for LPP_ADIPOQ |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for LPP_ADIPOQ |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| LPP | ATP5J2, PPP2R1A, ELAVL1, EGLN2, VHL, CLNS1A, PNPO, HNRNPL, CPT1A, HSPA5, AGFG1, ALAD, ARPC3, ARPC4, CALR, DBNL, HSPBP1, IPO11, P3H1, DPP9, EFTUD1, FEN1, FKBP10, RPRD1B, SAE1, SURF2, UFM1, NIF3L1, NPLOC4, OGT, PPME1, PPP2R5D, RANGAP1, RDX, SH3GLB1, TPRKB, UBE3A, ZPR1, SUZ12, RNF2, COPS5, GMPPA, PICALM, NINL, XPO1, CDH1, PTPN21, PPP2R3A, WDYHV1, SERPINB2, PDLIM7, LPXN, CBLC, MRPL38, WASF3, MTNR1A, G3BP1, TES | ADIPOQ | PDGFB, ADIPOQ, SGTA, CCDC155, SYNE4 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for LPP_ADIPOQ |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for LPP_ADIPOQ |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | LPP | C3495559 | Juvenile arthritis | 1 | CTD_human |
| Tgene | ADIPOQ | C0524620 | Metabolic Syndrome X | 4 | CTD_human |
| Tgene | ADIPOQ | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 3 | CTD_human |
| Tgene | ADIPOQ | C0018801 | Heart failure | 2 | CTD_human |
| Tgene | ADIPOQ | C0021655 | Insulin Resistance | 2 | CTD_human |
| Tgene | ADIPOQ | C0028754 | Obesity | 2 | CTD_human |
| Tgene | ADIPOQ | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
| Tgene | ADIPOQ | C0004153 | Atherosclerosis | 1 | CTD_human |
| Tgene | ADIPOQ | C0010346 | Crohn Disease | 1 | CTD_human |
| Tgene | ADIPOQ | C0011849 | Diabetes Mellitus | 1 | CTD_human |
| Tgene | ADIPOQ | C0011881 | Diabetic Nephropathy | 1 | CTD_human |
| Tgene | ADIPOQ | C0019337 | Heroin Dependence | 1 | CTD_human |
| Tgene | ADIPOQ | C0020452 | Hyperemia | 1 | CTD_human |
| Tgene | ADIPOQ | C0020538 | Hypertensive disease | 1 | CTD_human |
| Tgene | ADIPOQ | C0021368 | Inflammation | 1 | CTD_human |
| Tgene | ADIPOQ | C0022661 | Kidney Failure, Chronic | 1 | CTD_human |
| Tgene | ADIPOQ | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Tgene | ADIPOQ | C0027055 | Myocardial Reperfusion Injury | 1 | CTD_human |
| Tgene | ADIPOQ | C0034063 | Pulmonary Edema | 1 | CTD_human |
| Tgene | ADIPOQ | C0034069 | Pulmonary Fibrosis | 1 | CTD_human |
| Tgene | ADIPOQ | C0043094 | Weight Gain | 1 | CTD_human |
| Tgene | ADIPOQ | C0085207 | Gestational Diabetes | 1 | CTD_human |
| Tgene | ADIPOQ | C0151744 | Myocardial Ischemia | 1 | CTD_human |
| Tgene | ADIPOQ | C0400966 | Non-alcoholic Fatty Liver Disease | 1 | CTD_human |
| Tgene | ADIPOQ | C0948480 | Coronary Restenosis | 1 | CTD_human |
| Tgene | ADIPOQ | C0993582 | Arthritis, Experimental | 1 | CTD_human |
| Tgene | ADIPOQ | C1262477 | Weight decreased | 1 | CTD_human |
| Tgene | ADIPOQ | C1847529 | ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 3 | 1 | CTD_human |
| Tgene | ADIPOQ | C1847530 | ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 2 | 1 | CTD_human |
| Tgene | ADIPOQ | C2675517 | ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1 | 1 | UNIPROT |
| Tgene | ADIPOQ | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|